Evidence map›Paper›PMID 27999062›Full record

ArticleThe Journal of antimicrobial chemotherapy2017

5-Hydroxyethyl-3-tetradecanoyltetramic acid represents a novel treatment for intravascular catheter infections due to Staphylococcus aureus.

Marta Zapotoczna, Ewan J Murray, Siobhan Hogan, James P O'Gara, Siri R Chhabra, Weng C Chan, Eoghan O'Neill, Paul Williams

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Marta ZapotocznaDepartment of Clinical Microbiology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.
Ewan J MurraySchool of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham, UK.
Siobhan HoganDepartment of Clinical Microbiology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.
James P O'GaraDepartment of Microbiology, School of Natural Sciences, National University of Ireland, Galway, Ireland.
Siri R ChhabraSchool of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham, UK.
Weng C ChanSchool of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham, UK.
Eoghan O'NeillDepartment of Clinical Microbiology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.
Paul WilliamsSchool of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham, UK.
University of Nottingham · GBBeaumont Hospital · IECzech Academy of Sciences, Institute of Microbiology · CZ

Funding

Medical Research Council G9219778Medical Research Council MR/N010477/1
6 · The paper itself

Abstract

Objectives: Biofilm infections of intravascular catheters caused by Staphylococcus aureus may be treated with catheter lock solutions (CLSs). Here we investigated the antibacterial activity, cytotoxicity and CLS potential of 5-hydroxyethyl-3-tetradecanoyltetramic acid (5HE-C14-TMA) compared with the related compounds 3-tetradecanoyltetronic (C14-TOA) and 3-tetradecanoylthiotetronic (C14-TTA), which are variants of quorum sensing signalling molecules produced by Pseudomonas aeruginosa . Methods: Antibacterial activity and mechanism of action of 5HE-C14-TMA, C14-TOA and C14-TTA were determined via MIC, bacterial killing, membrane potential and permeability assays. Susceptibility of S. aureus biofilms formed in the presence of plasma in vitro was investigated, MTT cytotoxicity testing was undertaken and cytokine release in human blood upon exposure to 5HE-C14-TMA and/or S. aureus biofilms was quantified. The effectiveness of 5HE-C14-TMA as CLS therapy in vivo was assessed using a rat intravascular catheter biofilm infection model. Results: MICs of 5HE-C14-TMA, C14-TOA and C14-TTA ranged from 2 to 4 mg/L. 5HE-C14-TMA and C14-TTA were bactericidal; all three compounds perturbed the staphylococcal membrane by increasing membrane permeability, depolarized the transmembrane potential and caused ATP leakage. Cytotoxicity and haemolytic activity were compound and target cell type-dependent. 5HE-C14-TMA reduced S. aureus biofilm viability in a dose-dependent manner in vitro and in vivo and did not trigger release of cytokines in human blood, but inhibited the high levels of IL-8 and TNF-α induced by S. aureus biofilms. Conclusions: 5HE-C14-TMA, C14-TOA and C14-TTA are membrane-active agents. 5HE-C14-TMA was the most potent, eradicating S. aureus biofilms at 512-1024 mg/L both in vitro and in vivo as a CLS.

Indexed as

AnimalsAnti-Bacterial AgentsBiofilmsCatheter-Related InfectionsDrug DiscoveryHumansMicrobial Sensitivity TestsMicrobial ViabilityPseudomonas aeruginosaPyrrolidinonesQuorum SensingRatsStaphylococcal InfectionsStaphylococcus aureusVancomycinVascular Access Devices5-hydroxyethyl-3-tetradecanoyltetramic acidAnti-Bacterial AgentsPyrrolidinonesVancomycin

Identifiers

PMID27999062
PMCPMC5400099
OpenAlexW2561856561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.